Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D50NHR
|
|||
| Drug Name |
YW327.6S2
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Preclinical | [1] | |
| Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Preclinical | [1] | ||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tyrosine-protein kinase UFO (AXL) | Target Info | . | [1] |
| NetPath Pathway | FSH Signaling Pathway | |||
| Pathway Interaction Database | Validated transcriptional targets of deltaNp63 isoforms | |||
| Reactome | VEGFA-VEGFR2 Pathway | |||
| WikiPathways | miR-targeted genes in squamous cell - TarBase | |||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.